About ANI Pharmaceuticals
ANI Pharmaceuticals is a publicly listed company based in Baudette (United States) founded in 1996. Branded and generic prescription drugs are developed, manufactured, and marketed. ANI Pharmaceuticals has completed 5 acquisitions, including Alimera Sciences, H2-Pharma and Inderalxl. Its chief executive, as recorded, is Arthur Przybyl. Its website anipharmaceuticals.com draws about 17 thousand monthly visits. Its focus areas include Biopharma Outsourcing and Diversified.
Company details
ANI Pharmaceuticals was founded in 1996 and is headquartered in Baudette, United States. Operations focus on the pharmaceutical sector, where branded and generic prescription drugs are developed, manufactured, and marketed. A range of bio-pharmaceutical products is offered to address patient needs across various therapeutic areas. The company maintains a diversified portfolio to support healthcare providers and patients in the U.S. market.
- Headquarters Baudette, United States
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website anipharmaceuticals.com
- Social LinkedIn Facebook YouTube
- Investments & AcquisitionsAlimera Sciences
& 4 more
Apps and channels of ANI Pharmaceuticals
its YouTube channel ANI Pharmaceuticals has 35 subscribers.
People of ANI Pharmaceuticals
157 people are tracked at ANI Pharmaceuticals (76 in leadership, 6 in board & advisors, 75 in team).
| Name | Role | Group |
|---|---|---|
Arthur Przybyl | President & CEO | Leadership |
Stephen P. Carey | VP & CFO | Leadership |
Nikhil Lalwani | President, CEO & Board Member | Leadership |
L. Christopher Jung | Director, Strategic Development And Advocacy | Leadership |
Thom Rowland | Senior Vice President | Leadership |
Christoper Mutz | Chief Commercial Officer & Head of Rare Diseases | Leadership |
Brandy Albracht Hay | Area Business Director | Leadership |
Bsn Lance Leger | Area Business Director - Ophthalmology | Leadership |
Brett Kruiter | Sr. Director, Fp&a | Leadership |
Chadwick Carter | Area Business Director | Leadership |
Tracy Butcher | Field Reimbursement Director | Leadership |
Jake Austin | Vice President, US Sales | Leadership |
Jim Farrell | Sr. Director, National Accounts | Leadership |
Becca Loughlin | Director, HR Business Partner & Talent Development | Leadership |
Nirav Parekh | Director Incentive Compensation | Leadership |
Ryan Sydorko | Vp, Corporate Controller | Leadership |
Jennifer Brown | Field Reimbursement Director | Leadership |
Godien Ghobrial | Associate Director Commercial Analytics | Leadership |
Franco Vasciminno | Executive Director, Finance International | Leadership |
Edgar Escoto | Sr. Director, National Accounts | Leadership |
137 more people are available in the full profile.
Complete people profiles for ANI Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of ANI Pharmaceuticals
ANI Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol ANIP in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date15 May 2000
- Listed onNASDAQ: ANIP
- Listed entityANI Pharmaceuticals, Inc.
- Exchange sectorHealth technology
Investments & Acquisitions by ANI Pharmaceuticals
ANI Pharmaceuticals has strategically engaged in corporate development activities, having acquired 5 companies. Notable acquisitions include Alimera Sciences, H2-Pharma and Inderalxl.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Ophthalmic pharmaceuticals for diabetic macular edema are developed and commercialized. | alimerasciences.com | Alpharetta, United States | 2003 | Jul 2024 | •••• | |
Generic prescription medications are developed, manufactured, and distributed. | novitiumpharma.com | East Windsor, United States | 2016 | Mar 2021 | $163.5M | |
cGMP contract manufacturing and packaging of pharmaceuticals is offered. | wellspringcmo.com | Sarasota, United States | 2001 | Aug 2018 | $18M | |
Extended-release beta-blocker medication for hypertension is manufactured. | inderalxl.com | 0 | Feb 2017 | $23.3M | ||
Distributor of generic pharmaceutical drugs | h2-pharma.com | Montgomery, United States | 2013 | Feb 2016 | $10M |
Complete acquisition details for ANI Pharmaceuticals
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of ANI Pharmaceuticals
7 dated milestones of ANI Pharmaceuticals across 28 years, from founding to its latest funding, stage changes and deals.
- Founded ANI Pharmaceuticals is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires H2-Pharma.
- Acquisition Acquires Inderalxl.
- Acquisition Acquires WellSpring Pharma Services.
- Acquisition Acquires Novitium Pharma.
- Acquisition Acquires Alimera Sciences.
Web traffic of ANI Pharmaceuticals
The website of ANI Pharmaceuticals (anipharmaceuticals.com) receives about 16.7K visits a month and ranks #1,932,523 among all websites worldwide, #2,635 in Biotechnology and Pharmaceuticals.
- Monthly visits16.7K
▲ 36.3% vs previous month
- Unique visitors5.5K
per month
- Global rank#1,932,523
among all websites
- Category rank#2,635
Health · Biotechnology and Pharmaceuticals
- Bounce rate42%
- Pages per visit1.8
- Average visit49 sec
- DevicesDesktop 34% · Mobile 66%
Websites whose visitors overlap most with ANI Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| biosantepharma.com | 100% | 1.1K | #14,589,294 | View details | |
| otsuka.com | 75% | 47.2K | #682,452 | View details | |
| perrigo.com | 72% | 61.1K | #524,398 | View details | |
sante-bio.eu | sante-bio.eu | 50% | #5,178,739 | – | |
| geron.com | 44% | 11K | #2,181,363 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for ANI Pharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as ANI Pharmaceuticals (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ani Pharmaceuticals
Complete news archive for ANI Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ANI Pharmaceuticals
ANI Pharmaceuticals was founded in 1996.
ANI Pharmaceuticals is headquartered in Baudette, United States. It is registered at Baudette, Minnesota, United States.
Arthur Przybyl is the CEO of ANI Pharmaceuticals, as recorded in our data.
ANI Pharmaceuticals was founded in 1996 and is headquartered in Baudette, United States. Operations focus on the pharmaceutical sector, where branded and generic prescription drugs are developed, manufactured, and marketed. A range of bio-pharmaceutical products is offered to address patient needs across various therapeutic areas. The company maintains a diversified portfolio to support healthcare providers and patients in the U.S. market.
Yes, ANI Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol ANIP.
ANI Pharmaceuticals has made 5 acquisitions, including Alimera Sciences, H2-Pharma, and Inderalxl.